JT001 (VV116) for the Early Treatment of COVID-19

Exclusion Criteria

• •1. Participants who are judged by the investigator as likely to progress to severe/critical COVID-19 prior to randomization.
• •2. Participants who have SpO2≤93% on room air at sea level or PaO2/FiO2≤ 300, or respiratory rate ≥30 per minute, or heart rate ≥125 per minute
• •3. Participants who require mechanical ventilation or anticipated impending need for mechanical ventilation
• •4. Participants who are suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking intervention
• •5. Participants who have eye disease
• •6. Participants who have ALT or AST\>2 ULN at screening
• •7 Participants who have known allergies to any of the components used in the formulation of the interventions
• •8 Any medical condition, which in the opinion of the Investigator, will compromise the safety of the participant
• •9\. Participants who have received a SARS-CoV-2 monoclonal antibody treatment or prevention, or antiviral treatment (including the investigational treatment) within 180 days prior to screening visit
• •10\. Participants who have received convalescent COVID-19 plasma treatment
• •11\. Participants who have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed
• •12.Participants who are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
• •13\. Female who is pregnant or breast-feeding or plan to be pregnant within this study period